BG104149A - Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение - Google Patents

Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение

Info

Publication number
BG104149A
BG104149A BG104149A BG10414900A BG104149A BG 104149 A BG104149 A BG 104149A BG 104149 A BG104149 A BG 104149A BG 10414900 A BG10414900 A BG 10414900A BG 104149 A BG104149 A BG 104149A
Authority
BG
Bulgaria
Prior art keywords
binding proteins
interlevkin
administration
preparation
interleukin
Prior art date
Application number
BG104149A
Other languages
English (en)
Other versions
BG65519B1 (bg
Inventor
Daniela Novick
Charles Dinarello
Menachem Rubinstein
Soo Kim
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of BG104149A publication Critical patent/BG104149A/bg
Publication of BG65519B1 publication Critical patent/BG65519B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

Интерлевкин-18 свързващите белтъци свързват интерлевкин-18 и/или модулират, и/или блокират активността му. Изобретението се отнася и до методи за тяхното изолиране и рекомбинантна продукция, до кодиращи ги ДНК, експресиращи ги ДНК вектори, вектори, използвани за тяхната експресия в хора и други бозайници, както и до антитела срещу тях.
BG104149A 1997-08-14 2000-02-10 Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение BG65519B1 (bg)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use

Publications (2)

Publication Number Publication Date
BG104149A true BG104149A (bg) 2000-08-31
BG65519B1 BG65519B1 (bg) 2008-10-31

Family

ID=27517687

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104149A BG65519B1 (bg) 1997-08-14 2000-02-10 Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение

Country Status (28)

Country Link
US (4) US6605280B1 (bg)
EP (1) EP1003781B1 (bg)
JP (1) JP4272348B2 (bg)
KR (1) KR100687388B1 (bg)
CN (1) CN1243021C (bg)
AR (2) AR013422A1 (bg)
AT (1) ATE443719T1 (bg)
AU (1) AU755794B2 (bg)
BG (1) BG65519B1 (bg)
BR (1) BRPI9811940B8 (bg)
CA (1) CA2298855C (bg)
CY (1) CY1109664T1 (bg)
CZ (1) CZ300818B6 (bg)
DE (2) DE1003781T1 (bg)
DK (1) DK1003781T3 (bg)
EA (1) EA003675B1 (bg)
EE (1) EE05538B1 (bg)
ES (1) ES2149149T3 (bg)
HU (1) HU226698B1 (bg)
IL (5) IL121860A0 (bg)
NO (1) NO327240B1 (bg)
NZ (1) NZ502392A (bg)
PL (1) PL206070B1 (bg)
PT (1) PT1003781E (bg)
SI (1) SI1003781T1 (bg)
SK (1) SK287194B6 (bg)
UA (1) UA75862C2 (bg)
WO (1) WO1999009063A1 (bg)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
CA2324168A1 (en) * 1999-11-16 2001-05-16 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
PL356836A1 (en) 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
NZ535299A (en) * 2000-02-21 2006-06-30 Applied Research Systems Use of IL-18 inhibitors
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
CZ300792B6 (cs) * 2000-05-05 2009-08-12 Applied Research Systems Ars Holding N. V. Farmaceutický prostredek
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
KR100857376B1 (ko) * 2001-01-29 2008-09-05 라보라토리스 세로노 에스.에이. 심장 질환의 치료 및/또는 예방에 사용되는 ｉｌ-18저해물질
CN100556450C (zh) * 2001-05-16 2009-11-04 耶达研究发展有限公司 Il-18抑制剂在治疗或预防脓毒症中的应用
HRP20030842B1 (hr) * 2001-05-25 2017-06-02 Ares Trading S.A. UPOTREBA IL-18 INHIBITORA ZA LIJEČENJE I PREVENCIJU OZLJEDA CNS-a
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
SI1487541T1 (sl) * 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
MXPA05002219A (es) 2002-08-28 2005-07-05 Immunex Corp Composiciones y metodos para tratar una enfermedad cardiovascular.
US7279155B2 (en) * 2002-10-08 2007-10-09 Ares Trading S.A. Method of treatment using a cytokine able to bind IL-18BP to inhibit the activity of a second cytokine
IL152232A0 (en) * 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
CA2523912A1 (en) * 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
DK1622939T3 (da) * 2003-05-13 2012-04-10 Merck Serono Sa Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf
ES2285543T3 (es) 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
MXPA06005219A (es) 2003-11-12 2007-01-19 Univ Colorado Regents Composiciones y metodos para la regulacion del factor-alfa de necrosis tumoral.
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
DE602005002829T2 (de) * 2004-03-01 2008-07-10 Ares Trading S.A. Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
AU2005259269B2 (en) * 2004-06-29 2010-12-09 Ares Trading S.A. Process for the purification of IL-18 binding protein
ATE530227T1 (de) 2005-06-03 2011-11-15 Merck Serono Sa Verwendung von il-18bp-isoformen zur behandlung und/oder vorbeugung neurologischer entzündungskrankheiten
ES2385639T3 (es) 2005-06-03 2012-07-27 Ares Trading S.A. Producción de una proteína de unión a IL-18 recombinante
AU2006256763B2 (en) * 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
AU2007267213B2 (en) 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
CA2897067A1 (en) * 2013-01-02 2014-07-10 Wilsa, Inc. Method and apparatus for conditioning fluids
PT3041864T (pt) * 2013-09-05 2021-10-26 Ab2 Bio Sa Proteína de ligação a il-18 (il-18bp) em doenças inflamatórias
UA128752C2 (uk) 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CN120737196A (zh) * 2022-01-28 2025-10-03 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
AU2023236289A1 (en) * 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
JP2026503273A (ja) 2023-01-06 2026-01-28 ラッセン・セラピューティクス・インコーポレイテッド 抗ｉｌ－１８ｂｐ抗体
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
PT936923E (pt) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
JP4094066B2 (ja) 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
WO1998041232A2 (en) 1997-03-18 1998-09-24 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
ES2359401T3 (es) 1997-08-01 2011-05-23 Merck Serono Biodevelopment ESTs 5¿PARA PROTEÍNAS SECRETADAS, EXPRESADAS EN DIVERSOS TEJIDOS.
DE69834727T2 (de) 1997-08-01 2007-01-25 Serono Genetics Institute S.A. 5' ests für sekretierte proteine die in verschiedenen geweben expremiert werden
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
TR200101751T2 (tr) 1998-04-28 2002-05-21 Applied Research Systems Ars Holding N.V. Poliol-IFN-beta konjugatları
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
CZ2000490A3 (cs) 2000-08-16
CY1109664T1 (el) 2014-08-13
EA003675B1 (ru) 2003-08-28
HU226698B1 (en) 2009-07-28
JP2001514876A (ja) 2001-09-18
AU755794B2 (en) 2002-12-19
BRPI9811940B1 (pt) 2011-10-04
HUP0003533A2 (hu) 2001-01-29
HUP0003533A3 (en) 2003-08-28
BRPI9811940B8 (pt) 2021-07-06
NZ502392A (en) 2002-12-20
HK1028773A1 (en) 2001-03-02
BRPI9811940A (pt) 2000-09-05
US7799541B2 (en) 2010-09-21
PL338647A1 (en) 2000-11-06
DE1003781T1 (de) 2001-01-11
KR100687388B1 (ko) 2007-02-26
BG65519B1 (bg) 2008-10-31
CN1243021C (zh) 2006-02-22
IL134523A0 (en) 2001-04-30
AR062867A2 (es) 2008-12-10
ES2149149T3 (es) 2009-12-01
CN1267307A (zh) 2000-09-20
DE69841175D1 (de) 2009-11-05
US20040037829A1 (en) 2004-02-26
CA2298855C (en) 2014-05-27
DK1003781T3 (da) 2010-01-25
EP1003781A1 (en) 2000-05-31
AU8746098A (en) 1999-03-08
IL125463A0 (en) 1999-03-12
SI1003781T1 (sl) 2009-12-31
UA75862C2 (uk) 2006-06-15
PL206070B1 (pl) 2010-06-30
NO20000700D0 (no) 2000-02-11
ATE443719T1 (de) 2009-10-15
ES2149149T1 (es) 2000-11-01
EE05538B1 (et) 2012-04-16
EA200000216A1 (ru) 2000-08-28
PT1003781E (pt) 2009-10-26
IL122134A0 (en) 1998-04-05
SK287194B6 (sk) 2010-03-08
WO1999009063A1 (en) 1999-02-25
SK1762000A3 (en) 2000-09-12
US8436148B2 (en) 2013-05-07
NO327240B1 (no) 2009-05-18
IL121860A0 (en) 1998-02-22
EP1003781B1 (en) 2009-09-23
EE200000073A (bg) 2000-10-16
KR20010022900A (ko) 2001-03-26
US20100010200A1 (en) 2010-01-14
US6605280B1 (en) 2003-08-12
IL134523A (en) 2011-09-27
CZ300818B6 (cs) 2009-08-19
US20060154294A1 (en) 2006-07-13
NO20000700L (no) 2000-04-14
JP4272348B2 (ja) 2009-06-03
US7101689B2 (en) 2006-09-05
CA2298855A1 (en) 1999-02-25
AR013422A1 (es) 2000-12-27

Similar Documents

Publication Publication Date Title
EA200000216A1 (ru) Белки, связывающие интерлейкин-18, их получение и применение
ATE544776T1 (de) Chimäre dna-bindeproteine
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1112101T1 (el) Νευροτροφικοι παραγοντες
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
IL160142A0 (en) Methods and compounds for the targeting of protein to exosomes
DE69833014D1 (de) Menschliche toll homologen
DE60144145D1 (de) Subtilisin-variante
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
BG103091A (bg) ИЗТЕГЛЯЩ РАЗТВОРИМ ТУМОРЕН НЕКРОЗИСЕН ФАКТОР С РЕЦЕПТОРИ ТИП-i И ТИП-ii
ATE229542T1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
PT759942E (pt) Receptor de interleucina-15
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2003057821A3 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
WO2000059942A3 (en) Human obesity protein binding protrein-2 homolog and uses thereof
SE9604439D0 (sv) New receptor
EA200100110A1 (ru) Нейротрофические факторы
EA199900663A1 (ru) Новые белки, связывающиеся с рецептором 1 интерферона, кодирующая их днк и способы модуляции клеточного ответа на интерфероны
WO2001066738A3 (en) Nucleic acids, encoding human crsp1 and uses thereof
TW200635951A (en) Specific binding agents of human angiopoietin-2